Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Zai Lab Limited (9688.HK)
Shanghai, CN
Zai Lab Limited, established in 2013 and based in Shanghai, China, is a biopharmaceutical company dedicated to developing and bringing to market innovative medical treatments. Its core focus spans oncology, autoimmune diseases, infectious diseases, and neurological conditions, primarily serving patients in Mainland China and Hong Kong. The company's portfolio of commercialized products includes Zejula, an oral, once-daily poly polymerase 1/2 inhibitor; Optune, a non-invasive device employing tumor treating fields; NUZYRA for addressing acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia; and Qinlock, indicated for gastrointestinal stromal tumors. Zai Lab also maintains a robust pipeline of investigational therapies. This pipeline features numerous oncology assets such as Odronextamab for various lymphomas, Repotrectinib—a tyrosine kinase inhibitor targeting ROS1 and TRK fusions, Margetuximab for breast and gastroesophageal cancers, Adagrasib for KRAS-G12C-mutated solid tumors, and Bemarituzumab for gastric and gastroesophageal junction cancers. Other notable pipeline candidates include CLN-081 for specific non-small cell lung cancers, multi-targeted kinase inhibitors like Elzovantinib, several monoclonal antibodies (e.g., Tebotelimab, Retifanlimab, ZL-1201), and immune modulators such as Efgartigimod for reducing disease-causing IgG antibodies and ZL-1102 targeting IL-17A. Additionally, the company is advancing therapies like KarXT for psychiatric and neurological disorders, novel EGFR inhibitors (ZL-2313, ZL-2314), a CDC7 kinase inhibitor (ZL-2309), and Sulbactam/durlobactam for serious Acinetobacter infections, showcasing its commitment to a broad range of therapeutic innovations.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.66% | -7.28% | -7.51% | +3.51% | -12.87% | +10.11% | -32.60% | -45.25% | -87.38% | -75.36% | -75.36% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 7 | 0 |
| Hold | 2 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+15.5% ★ Q1'26: -6.7% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+38.5% ★ Q1'26: -14.8% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-58.1% Q1'26: -15.4% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-49.9% Q1'26: -69.7% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-140.5% Q1'26: -208.6% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+10.7% Q1'26: +2.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-1.15× Q1'26: -0.91× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 14 Rev. Ana. 3 EPS Ana. |
Dec 2027 16 Rev. Ana. 6 EPS Ana. |
Dec 2028 14 Rev. Ana. 3 EPS Ana. |
Dec 2029 15 Rev. Ana. 4 EPS Ana. |
Dec 2030 15 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
129.5K
est: 200.6K (-35.5%)
|
12.98M
est: 8.36M (+55.3%)
|
48.96M
est: 57.41M (-14.7%)
|
144.31M
est: 151.40M (-4.7%)
|
215.04M
est: 215.12M (0.0%)
|
266.72M
est: 266.50M (+0.1%)
|
398.99M
est: 393.10M (+1.5%)
|
460.84M
est: 462.82M (-0.4%)
|
467.74M
425.09M – 502.18M
+1.1% YoY
|
583.42M
498.36M – 757.26M
+24.7% YoY
|
748.66M
657.20M – 899.07M
+28.3% YoY
|
1.04B
915.86M – 1.25B
+39.4% YoY
|
1.38B
1.21B – 1.66B
+32.4% YoY
|
| EBITDA |
-138.45M
est: -184.9K (-74,761.0%)
|
-190.26M
est: -7.71M (-2,368.0%)
|
-262.97M
est: -52.92M (-396.9%)
|
-689.46M
est: -139.56M (-394.0%)
|
-384.66M
est: -198.30M (-94.0%)
|
-365.11M
est: -245.66M (-48.6%)
|
-242.99M
est: -318.87M (+23.8%)
|
-205.89M
est: -375.43M (+45.2%)
|
-379.41M
-407.34M – -344.81M
-1.1% YoY
|
-473.25M
-614.26M – -404.25M
-24.7% YoY
|
-607.28M
-729.29M – -533.09M
-28.3% YoY
|
-846.30M
-1.02B – -742.91M
-39.4% YoY
|
-1.12B
-1.35B – -983.88M
-32.4% YoY
|
| EBIT |
-138.45M
est: -186.1K (-74,280.8%)
|
-194.03M
est: -7.76M (-2,400.7%)
|
-267.61M
est: -53.26M (-402.4%)
|
-695.95M
est: -140.46M (-395.5%)
|
-392.89M
est: -199.58M (-96.9%)
|
-374.14M
est: -247.25M (-51.3%)
|
-254.85M
est: -325.28M (+21.7%)
|
-229.77M
est: -382.97M (+40.0%)
|
-387.04M
-415.53M – -351.75M
-1.1% YoY
|
-482.76M
-626.61M – -412.38M
-24.7% YoY
|
-619.49M
-743.95M – -543.81M
-28.3% YoY
|
-863.32M
-1.04B – -757.85M
-39.4% YoY
|
-1.14B
-1.37B – -1.00B
-32.4% YoY
|
| Net Income |
-139.07M
est: -141.51M (+1.7%)
|
-183.37M
est: -256.14M (+28.4%)
|
-298.16M
est: -303.54M (+1.8%)
|
-692.44M
est: -588.08M (-17.7%)
|
-481.99M
est: -484.95M (+0.6%)
|
-334.62M
est: -356.23M (+6.1%)
|
-257.10M
est: -296.74M (+13.4%)
|
-175.80M
est: -194.68M (+9.7%)
|
-215.97M
-553.87M – -43.02M
-10.9% YoY
|
-174.67M
-682.81M – 18.97M
+19.1% YoY
|
-107.57M
-135.67M – -90.48M
+38.4% YoY
|
-4.36M
-5.50M – -3.67M
+95.9% YoY
|
114.83M
96.59M – 144.82M
+2,734.2% YoY
|
| SGA |
21.58M
est: 272.8K (+7,808.8%)
|
70.21M
est: 11.37M (+517.4%)
|
111.31M
est: 78.07M (+42.6%)
|
218.83M
est: 205.87M (+6.3%)
|
258.97M
est: 292.52M (-11.5%)
|
281.61M
est: 362.38M (-22.3%)
|
298.74M
est: 403.21M (-25.9%)
|
278.02M
est: 474.72M (-41.4%)
|
479.76M
436.01M – 515.08M
+1.1% YoY
|
598.42M
511.17M – 776.73M
+24.7% YoY
|
767.90M
674.09M – 922.18M
+28.3% YoY
|
1.07B
939.41M – 1.29B
+39.4% YoY
|
1.42B
1.24B – 1.70B
+32.4% YoY
|
| EPS |
-2.64
est: -0.14 (-1,746.0%)
|
-3.03
est: -0.26 (-1,070.5%)
|
-3.46
est: -0.31 (-1,027.9%)
|
-7.58
est: -0.59 (-1,175.4%)
|
-4.63
est: -0.49 (-844.7%)
|
-3.46
est: -0.36 (-861.1%)
|
-0.26
est: -0.27 (+4.0%)
|
-0.16
est: -0.18 (+10.0%)
|
-0.20
-0.51 – -0.04
-10.9% YoY
|
-0.16
-0.62 – 0.02
+19.1% YoY
|
-0.10
-0.12 – -0.08
+38.4% YoY
|
0.00
-0.01 – 0.00
+95.9% YoY
|
0.10
0.09 – 0.13
+2,734.2% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ying Du | Founder, Chairperson & Chief Executive Officer | 13M | — |
| Joshua L. Smiley | President & Chief Operating Officer | 8M | male |
| Rafael G. Amado | President and Head of Global Research & Development | 8M | — |
| Frazor Titus Edmondson | Chief Legal Officer & Corporate Secretary | 7M | male |
| Yajing Chen | Chief Financial Officer | 6M | — |
| James Yan DABT | Chief Operating Officer of R&D | — | — |
| Christine Chiou | Senior Vice President & Head of Investor Relations | — | female |
| Shan He | Senior Vice President & Chief Business Officer | — | — |
| Tong Zhu | Chief Commercial Officer of Greater China | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 9688.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
